MedCAC To Examine ESAs In Chronic Kidney Disease, Pharmacogenomic Testing In Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The usage of erythropoiesis stimulating agents outside the renal setting is already subject to coverage limitations in Medicare.